Medication info
Zobacco Tablet (Simvastatin)

Zobacco Tablet (Simvastatin)

Prescription medicationTabletOral
Ingredient · strength
Simvastatin›20mg / 1 tablet
Manufacturer / importer
Korea Union Pharmaceutical Co., Ltd.
Appearance
Brownish-yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200401687 · Notified 2004.10.04 · Insurance code 665503800

Summary

Main use
Improvement of hyperlipidemia (including familial hyperlipidemia in children) and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
Patients must follow a standard cholesterol-lowering diet before and during treatment with this drug. 1. Reduction of cardiovascular risk Adult patients at high risk of coronary heart disease events due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Risk reduction in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended initial dose is 20 mg of this drug once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this drug. A dose of 5 ~ 40 mg of this drug once daily in the evening is recommended. Adjust the dose according to the initial LDL cholesterol level before treatment, the treatment target, and the patient's response to the drug. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if cholesterol levels fall below the target. Because of the increased risk of myopathy, including rhabdomyolysis, the 80 mg dose of this drug should be used only in patients who have taken 80 mg of this drug for 12 months or longer without evidence of muscle toxicity, particularly during the first year of treatment (see 1. Warnings under Precautions for Use). 2) For recommended doses in patients receiving this drug concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), see below (see 6. Interactions under Precautions for Use). (1) Use in patients with homozygous familial hypercholesterolemia Controlled clinical trial results indicate that patients with homozygous familial hypercholesterolemia should take 40 mg of this drug once daily in the evening. Use this drug in combination with other lipid-lowering treatments (e.g., LDL apheresis), or if other lipid-lowering treatments are not available. (2) In elderly patients, a daily dose of 20 mg of this drug may achieve the maximum reduction in cholesterol levels. (3) Use in patients receiving verapamil, diltiazem, or dronedarone When this drug is coadministered with verapamil, diltiazem, or dronedarone, the dose of this drug must not exceed 10 mg daily. (4) Use in patients receiving amiodarone, amlodipine, or ranolazine When this drug is coadministered with amiodarone, amlodipine, or ranolazine, the dose of this drug must not exceed 20 mg daily. (5) Concomitant use with other lipid-lowering drugs This drug is effective when used alone or in combination with bile acid sequestrants. When this drug is coadministered with fibrates (excluding gemfibrozil (see 2. Do not administer to the following patients under Precautions for Use) and fenofibrate), the dose of this drug must not exceed 10 mg daily. (6) Use in patients with renal impairment As this drug is not extensively excreted by the kidneys, no dose adjustment is required in patients with mild to moderate renal impairment. In patients with severe renal impairment, however, start with an initial dose of 5 mg daily and monitor carefully.
Child dose
Pediatric patients aged 10 ~ 17 years with heterozygous familial hypercholesterolemia: The recommended initial dose is 10 mg of this drug once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. Adjust the dose for each patient according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.

Ingredients

Manufacturer
Korea Union Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of hyperlipidemia (including familial hyperlipidemia in children) and prevention of cardiovascular disease

  • Coronary heart disease
  • diabetes
  • peripheral vascular disease
  • stroke
  • other cerebrovascular diseases
  • hypercholesterolemia
  • dyslipidemia
  • abnormal beta lipoproteinemia
  • hypertriglyceridemia
  • heterozygous familial hypercholesterolemia
View approved original text

This medication reduces the risk of cardiovascular disease in adults with a history of vascular-related diseases such as coronary heart disease, diabetes, peripheral vascular disease, and stroke. It also lowers the risk of death due to coronary heart disease, non-fatal myocardial infarction, and stroke, and decreases the risk associated with vascular interventions. In the treatment of hyperlipidemia, it lowers bad cholesterol levels and increases good cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia, thereby improving the balance of blood lipids. In children with familial hypercholesterolemia, it helps effectively manage cholesterol levels in conjunction with dietary therapy. Overall, these effects support the prevention and management of cardiovascular diseases.

How to take

Adult dose

Patients must follow a standard cholesterol-lowering diet before and during treatment with this drug. 1. Reduction of cardiovascular risk Adult patients at high risk of coronary heart disease events due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Risk reduction in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended initial dose is 20 mg of this drug once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this drug. A dose of 5 ~ 40 mg of this drug once daily in the evening is recommended. Adjust the dose according to the initial LDL cholesterol level before treatment, the treatment target, and the patient's response to the drug. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if cholesterol levels fall below the target. Because of the increased risk of myopathy, including rhabdomyolysis, the 80 mg dose of this drug should be used only in patients who have taken 80 mg of this drug for 12 months or longer without evidence of muscle toxicity, particularly during the first year of treatment (see 1. Warnings under Precautions for Use). 2) For recommended doses in patients receiving this drug concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), see below (see 6. Interactions under Precautions for Use). (1) Use in patients with homozygous familial hypercholesterolemia Controlled clinical trial results indicate that patients with homozygous familial hypercholesterolemia should take 40 mg of this drug once daily in the evening. Use this drug in combination with other lipid-lowering treatments (e.g., LDL apheresis), or if other lipid-lowering treatments are not available. (2) In elderly patients, a daily dose of 20 mg of this drug may achieve the maximum reduction in cholesterol levels. (3) Use in patients receiving verapamil, diltiazem, or dronedarone When this drug is coadministered with verapamil, diltiazem, or dronedarone, the dose of this drug must not exceed 10 mg daily. (4) Use in patients receiving amiodarone, amlodipine, or ranolazine When this drug is coadministered with amiodarone, amlodipine, or ranolazine, the dose of this drug must not exceed 20 mg daily. (5) Concomitant use with other lipid-lowering drugs This drug is effective when used alone or in combination with bile acid sequestrants. When this drug is coadministered with fibrates (excluding gemfibrozil (see 2. Do not administer to the following patients under Precautions for Use) and fenofibrate), the dose of this drug must not exceed 10 mg daily. (6) Use in patients with renal impairment As this drug is not extensively excreted by the kidneys, no dose adjustment is required in patients with mild to moderate renal impairment. In patients with severe renal impairment, however, start with an initial dose of 5 mg daily and monitor carefully.

Child dose

Pediatric patients aged 10 ~ 17 years with heterozygous familial hypercholesterolemia: The recommended initial dose is 10 mg of this drug once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. Adjust the dose for each patient according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.

Precautions

This medication may cause muscle abnormalities, so if muscle pain or weakness occurs, consult a doctor immediately. Especially when taken at high doses or in combination with certain drugs, the risk of myopathy may increase. Patients with liver dysfunction or liver disease should exercise caution as this medication may worsen liver function. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication. When taken with drugs that inhibit specific liver metabolic enzymes, blood concentration may increase, raising the risk of side effects; thus, consultation with a doctor is essential before combining medications. Patients who consume large amounts of alcohol or have liver impairment should exercise additional caution when taking this medication. Elderly patients and women have a higher risk of developing myopathy, requiring careful monitoring during use. This medication contains lactose, so patients with lactose intolerance should not take it. Regular liver function tests and muscle-related tests are recommended while taking this medication. If unexplained muscle pain, tenderness, or weakness occurs during use, stop taking it immediately and inform a doctor. Grapefruit juice may increase the concentration of this medication, so it should be avoided. If prescribed new medications while taking this medication, inform healthcare providers of this usage. In case of overdose, seek appropriate medical treatment immediately. Keep out of reach of children and store in the original container.

Side effects

Myopathy, rhabdomyolysis, abdominal pain, weakness, constipation, diarrhea, dyspepsia, bloating, nausea, headache, upper respiratory infection, edema, atrial fibrillation, gastritis, diabetes, myalgia, insomnia, dizziness, bronchitis, sinusitis, eczema, urinary tract infection, muscle cramps, arthralgia, taste disturbances, extraocular motility disorders, facial paresis, tremors, sensory disturbances, peripheral neuropathy, peripheral nerve palsy, mental disorders, anxiety, sleep disorders, nightmares, depression, cognitive impairment, myasthenia gravis, ocular myasthenia, hepatitis, liver dysfunction, jaundice, pancreatitis, liver failure, cholesterol-induced jaundice, liver fat changes, cirrhosis, fulminant liver necrosis, liver cancer, loss of appetite, vomiting, alopecia, pruritus, skin changes, lichen planus-like drug rash, gynecomastia, decreased libido, sexual dysfunction, cataract progression, ophthalmoplegia, anemia, elevated aminotransferases, elevated ALP, elevated γ-GTP, elevated bilirubin level, thyroid dysfunction, elevated creatine kinase, abnormal liver function tests, limb sensory loss, paresthesia, cold sensation, muscle weakness, thrombocytopenia, erythema lupus-like syndrome, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive antinuclear antibodies, increased erythrocyte sedimentation rate, eosinophilia, arthritis, urticaria, photophobia, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, interstitial lung disease, vomiting, mucoid stools, optic nerve degeneration, perivascular hemorrhage, perivascular edema, perivascular monocyte infiltration, perivascular fibrin deposition, small vessel necrosis, vestibular cochlear Wallerian-like degeneration, retinal ganglion cell chromatin lysis, vascular damage, muscle weakness, myalgia, elevated creatine kinase, myoglobinuria, acute renal failure, myalgia, tenderness, muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air ingress, at a temperature between 1°C and 30°C. Storing it this way helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Brownish-yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.